Evidence map›Paper›PMID 37084714›Full record

ArticleMolecular cell2023

Uncoupled glycerol-3-phosphate shuttle in kidney cancer reveals that cytosolic GPD is essential to support lipid synthesis.

Cong-Hui Yao, Joon Seok Park, Kiran Kurmi, Song-Hua Hu, Giulia Notarangelo, Joseph Crowley, Heidi Jacobson, Sheng Hui, Arlene H Sharpe, Marcia C Haigis

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cell, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 39 citations in OpenAlex.

  1. Reply to Lemieux et al.: Integration does not preclude essentiality of mitochondrial glycerol-3-phosphate dehydrogenase.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Cong-Hui YaoDepartment of Cell Biology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
Joon Seok ParkDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA; Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.
Kiran KurmiDepartment of Cell Biology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
Song-Hua HuDepartment of Cell Biology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
Giulia NotarangeloDepartment of Cell Biology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
Joseph CrowleyDepartment of Cell Biology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
Heidi JacobsonDepartment of Cell Biology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
Sheng HuiDepartment of Molecular Metabolism, Harvard T. H. Chan School of Public Health, Boston, MA, USA.
Arlene H SharpeDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA; Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.
Marcia C HaigisDepartment of Cell Biology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA. Electronic address: marcia_haigis@hms.harvard.edu.
Harvard University · USBrigham and Women's Hospital · US

Funding

Systems Pharmacology of Therapeutic and Adverse Responses to ImmuneCheckpoint and Small Molecule DrugsU54CA225088 · NCI · HARVARD MEDICAL SCHOOL · PI LATORRE, ISABEL · 2018 to 2022
$10.8M
Sirtuins and CancerR01CA273461 · NCI · HARVARD MEDICAL SCHOOL · PI MARCIA HAIGIS · 2022 to 2026
$2.9M
Molecular mechanisms of Nutrient sensing in cancerR01CA213062 · NCI · HARVARD MEDICAL SCHOOL · PI HAIGIS, MARCIA · 2017 to 2021
$1.9M
NCI NIH HHS R01 CA213062NCI NIH HHS R01 CA273461NCI NIH HHS U54 CA225088
6 · The paper itself

Abstract

The glycerol-3-phosphate shuttle (G3PS) is a major NADH shuttle that regenerates reducing equivalents in the cytosol and produces energy in the mitochondria. Here, we demonstrate that G3PS is uncoupled in kidney cancer cells where the cytosolic reaction is ∼4.5 times faster than the mitochondrial reaction. The high flux through cytosolic glycerol-3-phosphate dehydrogenase (GPD) is required to maintain redox balance and support lipid synthesis. Interestingly, inhibition of G3PS by knocking down mitochondrial GPD (GPD2) has no effect on mitochondrial respiration. Instead, loss of GPD2 upregulates cytosolic GPD on a transcriptional level and promotes cancer cell proliferation by increasing glycerol-3-phosphate supply. The proliferative advantage of GPD2 knockdown tumor can be abolished by pharmacologic inhibition of lipid synthesis. Taken together, our results suggest that G3PS is not required to run as an intact NADH shuttle but is instead truncated to support complex lipid synthesis in kidney cancer.

Indexed as

Glycerol-3-Phosphate Dehydrogenase (NAD+)Kidney NeoplasmsLipidsGlycerolGlycerolphosphate DehydrogenaseHumansNADOxidation-ReductionPhosphatesGlycerolGlycerol-3-Phosphate Dehydrogenase (NAD+)Glycerolphosphate DehydrogenaseLipidsNADPhosphatesglycerolglycerol-3-phosphate dehydrogenaseglycerol-3-phosphate shuttleGPDkidney cancerlipidsmetabolismmitochondriaNAD

Identifiers

PMID37084714
PMCPMC10131091
OpenAlexW4366484362

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.